Clinical Scorecard: Unexpected Improvement of Cystoid Macular Edema Accompanied by Axial Elongation in a Child with Usher Syndrome Type 1B: A Case Study

At a Glance

Key Highlights

• USH1B is characterized by early-onset RP, profound congenital SNHL, and vestibular hypoplasia.
• Cystoid macular edema occurs in 10–50% of RP patients and is a treatable cause of vision loss.
• Conservative management with refractive correction alone led to spontaneous CME resolution in a 3-year-old USH1B patient.

Guideline-Based Recommendations

Diagnosis

• Genetic testing confirming pathogenic variants in MYO7A gene confirms USH1B diagnosis.
• Ophthalmic examination including visual acuity, slit-lamp, fundus exam, and OCT to detect CME and retinal changes.
• Consider ERG for functional retinal assessment when feasible.

Management

• First-line therapy for RP-associated CME is carbonic anhydrase inhibitors, based on adult data.
• Intravitreal steroids and anti-VEGF agents may be used in refractory cases but lack established safety in children.
• Conservative management with refractive correction may be considered in pediatric patients, with individualized risk-benefit assessment.

Monitoring & Follow-up

• Regular follow-up with OCT to monitor CME status and retinal morphology.
• Axial length measurements to observe ocular growth changes.
• Visual acuity assessments to track functional vision.

Risks

• Progressive vision loss due to RP and CME if untreated.
• Potential adverse effects of intravitreal therapies in pediatric patients remain unestablished.
• Delayed motor development and vestibular dysfunction may complicate clinical management.

Patient & Prescribing Data

Pediatric patients with USH1B presenting with CME

Spontaneous and sustained resolution of CME observed with refractive correction alone over 9 months, highlighting potential for intrinsic retinal recovery and need for cautious therapeutic intervention.

Clinical Best Practices

• Confirm USH subtype via genetic analysis for accurate diagnosis and prognosis.
• Perform comprehensive ophthalmic evaluation including OCT to detect CME early.
• Consider conservative management with refractive correction in pediatric CME before initiating pharmacologic therapy.
• Monitor axial length and visual acuity regularly to assess disease progression and treatment response.
• Individualize treatment decisions weighing potential benefits and risks, especially regarding invasive therapies in children.

References

• Usher syndrome classification and genetics
• Cystoid macular edema in retinitis pigmentosa
• Management of RP-associated CME